Literature DB >> 21992851

Long-term outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.

Keiichi Ishida1, Masahisa Masuda, Nobuhiro Tanabe, Goro Matsumiya, Koichiro Tatsumi, Nobuyuki Nakajima.   

Abstract

OBJECTIVES: Pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension. Although several reports demonstrated excellent medium-term survival after pulmonary endarterectomy, long-term outcomes remain unclear. We reviewed long-term outcomes and determined risk factors for early and late adverse events.
METHODS: Seventy-seven patients were studied. Mean pulmonary arterial pressure was 47±10 mm Hg and pulmonary vascular resistance was 868±319 dyne·s·cm(-5). Disease was classified as chronic thromboembolic pulmonary hypertension type 1 (n=61), type 2 (n=12), or type 3 (n=4). Median and maximum follow-up periods were 5.6 and 20 years, respectively.
RESULTS: There were 11 in-hospital deaths. Nonsurvivors had significantly higher mean pulmonary arterial pressure and pulmonary vascular resistance than did survivors (54±10 vs 46±10 mm Hg; P=.02; 1124±303 vs 824±303 dyne·s·cm(-5); P<.01). In multivariate analysis, preoperative pulmonary vascular resistance was associated with in-hospital death (odds ratio, 1.003; 95% confidence interval, 1.001-1.005; P<.01). During follow-up, there were 10 all-cause deaths, including 5 related to chronic thromboembolic pulmonary hypertension. Freedom from adverse events, including disease-specific death or New York Heart Association functional class III, was 70% at 10 years. In the Cox proportional hazard model, postoperative mean pulmonary arterial pressure was associated with adverse events (hazard ratio, 1.12; 95% confidence interval, 1.03-1.21; P<.01). Receiver operating characteristic curve analysis showed mean pulmonary arterial pressure of 34 mm Hg as cutoff for adverse events.
CONCLUSIONS: Pulmonary endarterectomy had sustained favorable effects on long-term survival. High pulmonary vascular resistance was associated with in-hospital death, and postoperative mean pulmonary arterial pressure was an independent predictor of adverse events.
Copyright © 2012 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21992851     DOI: 10.1016/j.jtcvs.2011.09.004

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  15 in total

1.  Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From the United Kingdom National Cohort.

Authors:  John E Cannon; Li Su; David G Kiely; Kathleen Page; Mark Toshner; Emilia Swietlik; Carmen Treacy; Anie Ponnaberanam; Robin Condliffe; Karen Sheares; Dolores Taboada; John Dunning; Steven Tsui; Choo Ng; Deepa Gopalan; Nicholas Screaton; Charlie Elliot; Simon Gibbs; Luke Howard; Paul Corris; James Lordan; Martin Johnson; Andrew Peacock; Robert MacKenzie-Ross; Benji Schreiber; Gerry Coghlan; Kostas Dimopoulos; Stephen J Wort; Sean Gaine; Shahin Moledina; David P Jenkins; Joanna Pepke-Zaba
Journal:  Circulation       Date:  2016-04-06       Impact factor: 29.690

Review 2.  State of the art: utility of multi-energy CT in the evaluation of pulmonary vasculature.

Authors:  Prabhakar Rajiah; Yuki Tanabe; Sasan Partovi; Alastair Moore
Journal:  Int J Cardiovasc Imaging       Date:  2019-05-02       Impact factor: 2.357

Review 3.  Surgical Management of Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Andrew M Vekstein; Joseph R Nellis; Sharon L McCartney; John C Haney
Journal:  Cardiol Clin       Date:  2022-02       Impact factor: 2.213

Review 4.  Recent advances of pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension including Japanese experiences.

Authors:  Hitoshi Ogino
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-09-26

Review 5.  Balloon pulmonary angioplasty vs. pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis.

Authors:  Liyan Zhang; Yuping Bai; Peijing Yan; Tingting He; Bin Liu; Shanlian Wu; Zhen Qian; Changtian Li; Yunshan Cao; Min Zhang
Journal:  Heart Fail Rev       Date:  2021-02-05       Impact factor: 4.214

6.  Quantifying the learning curve for pulmonary thromboendarterectomy.

Authors:  Smita Sihag; Bao Le; Alison S Witkin; Josanna M Rodriguez-Lopez; Mauricio A Villavicencio; Gus J Vlahakes; Richard N Channick; Cameron D Wright
Journal:  J Cardiothorac Surg       Date:  2017-12-28       Impact factor: 1.637

7.  Riociguat Improves Pulmonary Hemodynamics in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Cheng-Hsuan Tsai; Cho-Kai Wu; Ping-Hung Kuo; Hsao-Hsun Hsu; Zheng-Wei Chen; Juey-Jen Hwang; Chi-Lun Ko; Yu-Sen Huang; Yen-Hung Lin
Journal:  Acta Cardiol Sin       Date:  2020-01       Impact factor: 2.672

8.  Evaluation of the Microcirculation in Chronic Thromboembolic Pulmonary Hypertension Patients: The Impact of Pulmonary Arterial Remodeling on Postoperative and Follow-Up Pulmonary Arterial Pressure and Vascular Resistance.

Authors:  Takayuki Jujo; Seiichiro Sakao; Hatsue Ishibashi-Ueda; Keiichi Ishida; Akira Naito; Toshihiko Sugiura; Ayako Shigeta; Nobuhiro Tanabe; Masahisa Masuda; Koichiro Tatsumi
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

9.  The Clinical Significance of HbA1c in Operable Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Manuel Jonas Richter; Katrin Milger; Sarah Haase; Natascha Sommer; Khodr Tello; Werner Seeger; Eckhard Mayer; Christoph Benjamin Wiedenroth; Friedrich Grimminger; Wolfgang George; Hossein Ardeschir Ghofrani; Stefan Guth; Henning Gall
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

10.  Severe Pulmonary Arteriopathy Is Associated with Persistent Hypoxemia after Pulmonary Endarterectomy in Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Takayuki Jujo; Nobuhiro Tanabe; Seiichiro Sakao; Hatsue Ishibashi-Ueda; Keiichi Ishida; Akira Naito; Fumiaki Kato; Takao Takeuchi; Ayumi Sekine; Rintaro Nishimura; Toshihiko Sugiura; Ayako Shigeta; Masahisa Masuda; Koichiro Tatsumi
Journal:  PLoS One       Date:  2016-08-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.